Proliferação monoclonal B CD5+ subclínica Monoclonal B CD5+ subclinical proliferation

Abstract

O termo proliferação monoclonal B CD5+ subclínica refere-se a um conjunto de entidades clínicas ou laboratoriais descritas em indivíduos normais (0,14%-5,5%), em familiares de pacientes com leucemia linfocítica crônica familiar (13,5% a 18%) e em pacientes com linfocitose B monoclonal no sangue periférico mas com contagens Monoclonal B CD5+ subclinical proliferation is related to a group of clinical or laboratory entities described in normal subjects (0.14%-5.5%), in normal members of families with cases of familial CLL (13.5%-18%) and in patients with monoclonal B lympho­cytosis with lymphocyte counts of <5 x 10(9)/L and with <30% of lymphocytes in bone marrow. These three entities are now named monoclonal B-cell lymphocytosis. Additionally, there are cases that fulfill the diagnostic criteria for CLL but present with stable non-progressive disease and are also named as benign monoclonal B lymphocytosis, smoldering CLL, idiopathic persistent chronic lymphocytosis, and B-monoclonal lympho­cytosis of undetermined significance.

Keywords

• Leucemia linfocítica crônica
• linfocitose B monoclonal
• Chronic lymphocytic leukemia
• monoclonal B lymphocytosis